StudyFinder

Clear

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

Search all categories
541 Study Matches

PSCI 23-023 A PHASE III, MULTICENTER, RANDOMIZED, OPEN‑LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE (POLA-R-CHP) VERSUS POLA‑R‑CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA

To see if using glofitamab added to chemotherapy is better than chemotherapy alone.

Participants will be required to come to all study visits, report any new medications, prescription or over the counter that they are taking, make sure to tell the study doctor of any new symptoms you may be having.

$180/visit, $130 follow up visit

Yes
 
Seema Naik
PSCI-CTO@pennstatehealth.psu.edu 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT06047080
STUDY00025739
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 1880 years at the time of signing Informed Consent Form and willingness to comply with study protocol procedures
Previously untreated participants with CD20-positive LBCL
IPI score 2-5
ECOG Performance Status of 0, 1, or 2
Life expectancy >/= 6 months
Exclusion Criteria:
Prior solid organ transplantation
Current Grade > 1 peripheral neuropathy by clinical examination or demyelinating form of Charcot-Marie-Tooth disease
receiving systemic immunosuppressive agents
Significant or extensive history of cardiovascular disease
Cancer
Experimental drug compared to an approved drug
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,